Molecular Pharmacology (USA) Ltd
Molecular Pharmacology (USA), Ltd., a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in v… Read more
Molecular Pharmacology (USA) Ltd (MLPH) - Total Assets
Latest total assets as of September 2014: $8.84K USD
Based on the latest financial reports, Molecular Pharmacology (USA) Ltd (MLPH) holds total assets worth $8.84K USD as of September 2014.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Molecular Pharmacology (USA) Ltd - Total Assets Trend (2004–2014)
This chart illustrates how Molecular Pharmacology (USA) Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Molecular Pharmacology (USA) Ltd - Asset Composition Analysis
Current Asset Composition (June 2014)
Molecular Pharmacology (USA) Ltd's total assets of $8.84K consist of 98.9% current assets and 1.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.5% |
| Accounts Receivable | $6.49K | 72.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $97.00 | 1.1% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2014)
This chart illustrates how Molecular Pharmacology (USA) Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Molecular Pharmacology (USA) Ltd's current assets represent 98.9% of total assets in 2014, an increase from 40.9% in 2004.
- Cash Position: Cash and equivalents constituted 26.5% of total assets in 2014, down from 40.9% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 72.4% of total assets.
Molecular Pharmacology (USA) Ltd Competitors by Total Assets
Key competitors of Molecular Pharmacology (USA) Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $281.56 Million |
|
Azure Holding Group Corp
PINK:AZRH
|
USA | $16.92 Million |
|
Constellation Capital Corp.
V:CNST-P
|
Canada | CA$627.53K |
|
Little Fish Acquisition I Corp.
V:LILL-P
|
Canada | CA$56.48K |
|
Hana 30 Special Purpose Acquisition Company
KQ:469880
|
Korea | ₩17.89 Billion |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
Molecular Pharmacology (USA) Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Molecular Pharmacology (USA) Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Molecular Pharmacology (USA) Ltd is currently not profitable relative to its asset base.
Molecular Pharmacology (USA) Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.01 | 0.56 |
| Quick Ratio | 0.00 | 0.01 | 0.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.10 Million | $ -2.13 Million | $ -12.37K |
Molecular Pharmacology (USA) Ltd - Advanced Valuation Insights
This section examines the relationship between Molecular Pharmacology (USA) Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -26.8% |
| Total Assets | $8.97K |
| Market Capitalization | $3.73 USD |
Valuation Analysis
Below Book Valuation: The market values Molecular Pharmacology (USA) Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Molecular Pharmacology (USA) Ltd's assets decreased by 26.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Molecular Pharmacology (USA) Ltd (2004–2014)
The table below shows the annual total assets of Molecular Pharmacology (USA) Ltd from 2004 to 2014.
| Year | Total Assets | Change |
|---|---|---|
| 2014-06-30 | $8.97K | -26.83% |
| 2013-06-30 | $12.26K | +38.63% |
| 2012-06-30 | $8.84K | -47.65% |
| 2011-06-30 | $16.89K | +44.95% |
| 2010-06-30 | $11.65K | -12.91% |
| 2009-06-30 | $13.38K | -71.81% |
| 2007-06-30 | $47.47K | +113.56% |
| 2006-06-30 | $22.23K | -0.55% |
| 2004-06-30 | $22.35K | -- |